Both retatrutide and tirzepatide are listed for research use in both the EU and US channels
A healthcare provider can help you decide which option best balances effectiveness, lifestyle preferences, and safety based on your personal health history
Oral dosing eliminates needle-related bruising entirely, though it has slightly lower absorption rates
Safety considerations BPC-157 has shown a strong safety profile in animal studies with no toxic dose identified, but dosing should always involve a physician because animal data does not translate directly, individual factors affect response, and product quality varies
In 2022, the FDA added both semaglutide and tirzepatide to its drug-shortage list
Prepared by FDA-registered, state-board-regulated pharmacies in ISO-classified cleanrooms